{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:07:27Z","timestamp":1784866047549,"version":"3.55.0"},"reference-count":26,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v104.18348","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T09:31:31Z","timestamp":1705915891000},"page":"adv18348","source":"Crossref","is-referenced-by-count":19,"title":["Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients"],"prefix":"10.2340","volume":"104","author":[{"given":"Takafumi","family":"Numata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryokichi","family":"Irisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"47253","doi-asserted-by":"crossref","unstructured":"Fukuyama M, Ito T, Ohyama M. Alopecia areata: current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol 2022; 49: 19-36.","DOI":"10.1111\/1346-8138.16207"},{"key":"47254","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.16207","DOI":"10.1111\/1346-8138.16207"},{"key":"47255","doi-asserted-by":"crossref","unstructured":"Harries M, Macbeth AE, Holmes S, Chiu WS, Gallardo WR, Nijher M, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol 2022; 186: 257-265.","DOI":"10.1111\/bjd.20628"},{"key":"47256","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.20628","DOI":"10.1111\/bjd.20628"},{"key":"47257","doi-asserted-by":"crossref","unstructured":"Lee S, Kim BJ, Lee YB, Lee WS. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol 2018; 154: 1145-1151.","DOI":"10.1001\/jamadermatol.2018.2312"},{"key":"47258","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.2312","DOI":"10.1001\/jamadermatol.2018.2312"},{"key":"47259","doi-asserted-by":"crossref","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021; 6: 402.","DOI":"10.1038\/s41392-021-00791-1"},{"key":"47260","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41392-021-00791-1","DOI":"10.1038\/s41392-021-00791-1"},{"key":"47261","doi-asserted-by":"crossref","unstructured":"Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK inhibitors for treatment of alopecia areata. J Invest Dermatol 2018; 138: 1911-1916.","DOI":"10.1016\/j.jid.2018.05.027"},{"key":"47262","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2018.05.027","DOI":"10.1016\/j.jid.2018.05.027"},{"key":"47263","doi-asserted-by":"crossref","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699.","DOI":"10.1056\/NEJMoa2110343"},{"key":"47264","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2110343","DOI":"10.1056\/NEJMoa2110343"},{"key":"47265","doi-asserted-by":"crossref","unstructured":"De Greef A, Thirion R, Ghislain PD, Baeck M. Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data. Dermatol Ther (Heidelb) 2023; 13: 2869-2877.","DOI":"10.1007\/s13555-023-01030-x"},{"key":"47266","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-023-01030-x","DOI":"10.1007\/s13555-023-01030-x"},{"key":"47267","doi-asserted-by":"crossref","unstructured":"Zhan J, Cao J, Chen F, Jin Y, Huang C. Real-data on the use of baricitinib in adolescents with severe alopecia areata. J Eur Acad Dermatol Venereol 2023; 10.1111\/jdv.19121.","DOI":"10.1111\/jdv.19121"},{"key":"47268","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19121","DOI":"10.1111\/jdv.19121"},{"key":"47269","doi-asserted-by":"crossref","unstructured":"Moussa A, Eisman S, Sinclair RD, Bhoyrul B. Treatment of alopecia areata of the beard with baricitinib. J Am Acad Dermatol 2023; 88: 948-950.","DOI":"10.1016\/j.jaad.2022.11.028"},{"key":"47270","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.028","DOI":"10.1016\/j.jaad.2022.11.028"},{"key":"47271","doi-asserted-by":"crossref","unstructured":"Gargiulo L, Ibba L, Vignoli CA, Ferrucci SM, Mercuri SR, Malagoli P, et al. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat 2023; 34: 2268764.","DOI":"10.1080\/09546634.2023.2268764"},{"key":"47272","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2023.2268764","DOI":"10.1080\/09546634.2023.2268764"},{"key":"47273","doi-asserted-by":"crossref","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440-447.","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"47274","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2003.09.032","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"47275","doi-asserted-by":"crossref","unstructured":"Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, et al. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat 2023; 34: 2227299.","DOI":"10.1080\/09546634.2023.2227299"},{"key":"47276","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2023.2227299","DOI":"10.1080\/09546634.2023.2227299"},{"key":"47277","doi-asserted-by":"crossref","unstructured":"Roest YBM, van Middendorp HT, Evers AWM, van de Kerkhof PCM, Pasch MC. Nail involvement in alopecia areata: a questionnaire-based survey on clinical signs, impact on quality of life and review of the literature. Acta Derm Venereol 2018; 98: 212-217.","DOI":"10.2340\/00015555-2810"},{"key":"47278","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2810","DOI":"10.2340\/00015555-2810"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/18348\/45124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/18348\/45124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T09:31:44Z","timestamp":1705915904000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/18348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.18348","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}